UK markets open in 3 hours 39 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
112.33-1.84 (-1.61%)
At close: 4:00PM EST

109.00 -3.33 (-2.96%)
After hours: 7:59PM EST

Full screen
Trade prices are not sourced from all markets
Previous close114.17
Open114.87
Bid108.80 x 900
Ask112.69 x 800
Day's range111.18 - 117.30
52-week range28.00 - 131.00
Volume1,129,800
Avg. volume3,318,958
Market cap27.047B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date10 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est120.44
  • Pfizer-BioNTech testing booster of their COVID-19 vaccine in new trial
    Reuters

    Pfizer-BioNTech testing booster of their COVID-19 vaccine in new trial

    Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are also in talks with regulatory authorities about testing a vaccine modified to protect specifically against the highly transmissible new variant found in South Africa and elsewhere, known as B.1.351, as a second arm of the same study. The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere.

  • Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
    Business Wire

    Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the opportunity to receive a 30 µg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen. The study is part of the Companies’ clinical development strategy to determine the effectiveness of a third dose against evolving variants.

  • Moderna expands vaccine production, sets 2022 target of 1.4B doses
    Yahoo Finance

    Moderna expands vaccine production, sets 2022 target of 1.4B doses

    Moderna announces new expansion plans, and a study for its booster shot that targets the South African variant.